Silke Gronau

Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma

Herbert Riechelmann, Alexander Sauter, Wolfram Golze et al. · Oral Oncology · 2008 · 199 citations

Medicine, Oncology, Pharmacology +12

Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck

Alexander Sauter, Charlotte Kloft, Silke Gronau et al. · International Journal of Oncology · 2007 · 59 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Nasal Toxicity of Benzalkonium Chloride

Herbert Riechelmann, Tom Deutschle, Anja Stuhlmiller et al. · American Journal of Rhinology · 2004 · 55 citations

Medicine, Pharmacology, Toxicology +13

Immunohistomorphologic and molecular cytogenetic analysis of a carcinosarcoma of the urinary bladder

Silke Gronau, Christiane K. Menz, Ingo Melzner et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2002 · 41 citations

Medicine, Oncology, Pathology +14

Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial

Herbert Riechelmann, Markus Wiesneth, Peter Schauwecker et al. · Cancer Immunology Immunotherapy · 2007 · 30 citations · Full text

Medicine, Immunology, Oncology +16